Skip to search formSkip to main contentSkip to account menu

TMC 435350

Known as: 435350, TMC, TMC-435350, TMC435350 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

simeprevir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Pharmacokinetic / Pharmacodynamic Predictors of Clinical Potency for 1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3
1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3 Authors: Micaela B. Reddy, Peter N. Morcos, Sophie Le Pogam… 
2010
2010
Haemo- and cytocompatibility of bioresorbable homo- and copolymers prepared from 1,3-trimethylene carbonate, lactides, and epsilon-caprolactone.
A series of bioresorbable polymers were prepared by ring-opening polymerization of L-lactide (LLA), DL-lactide (DLLA), epsilon… 
2009
2009
Running title: TMC435350, in vitro activity and pre-clinical profile
2009
2009
Gateways to clinical trials.
ABT-869, Acadesine, Acetylsalicylic acid/omeprazole, Adefovir, Adefovir dipivoxil, AEG-35156, Agatolimod sodium, Albiglutide… 
2008
2008
65 CLONAL ANALYSIS OF MUTATIONS SELECTED IN THE HCV NS3 PROTEASE DOMAIN OF GENOTYPE 1 NON-RESPONDERS TREATED WITH BOCEPREVIR (SCH503034)
2008
2008
64 SAFETY OF THE HCV PROTEASE INHIBITOR TMC435350 IN HEALTHY VOLUNTEERS AND SAFETY AND ACTIVITY IN CHRONIC HEPATITIS C INFECTED INDIVIDUALS: A PHASE I STUDY
2008
2008
855 ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA AND LIVER
2007
2007
Results of a Phase I Placebo-Controlled Trial in Healthy Volunteers to Examine the Safety, Tolerability and PK of the HCV Protease Inhibitor TMC435350 after Single and Repeated Dosing
t max, hour* 5.0 (3.0 - 6.0) 5.0 (4.0 - 6.0) 6.0 (4.0 - 6.0) 6.0 (4.0 - 6.0) 6.0 (4.0 - 6.0) 6.0 (4.0 - 6.0) 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)